Brokerages Set Progyny, Inc. (NASDAQ:PGNY) Price Target at $25.30

Key Points

• Progyny, Inc. has received an average brokerage recommendation of "Moderate Buy" from eleven rating firms, with a consensus price target of $25.30.
• Recent analyst updates include Cantor Fitzgerald and Leerink Partners both maintaining optimistic price targets of $28.00 for the stock.
• In the last 90 days, company insiders have sold a total of 7,895 shares, indicating significant insider activity, with 9.40% of the stock being held by insiders.

Progyny, Inc. (NASDAQ:PGNY - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eleven brokerages that are currently covering the company, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $25.30.

A number of equities analysts have issued reports on the company. Canaccord Genuity Group upped their target price on Progyny from $21.00 to $23.00 and gave the company a "hold" rating in a research report on Wednesday, August 20th. JPMorgan Chase & Co. upped their price target on shares of Progyny from $23.00 to $25.00 and gave the company a "neutral" rating in a report on Tuesday, August 26th. Leerink Partners upgraded shares of Progyny from a "market perform" rating to an "outperform" rating and set a $28.00 price objective on the stock in a research note on Tuesday, July 8th. Cantor Fitzgerald reissued an "overweight" rating and set a $28.00 price objective (up from $26.00) on shares of Progyny in a report on Friday, August 8th. Finally, Raymond James Financial set a $28.00 target price on shares of Progyny in a research report on Friday, August 8th.

Progyny Stock Down 1.6%

Shares of NASDAQ PGNY traded down $0.36 during trading on Thursday, reaching $21.77. 1,744,719 shares of the stock were exchanged, compared to its average volume of 875,684. Progyny has a twelve month low of $13.39 and a twelve month high of $26.76. The company has a market capitalization of $1.87 billion, a price-to-earnings ratio of 36.90, a price-to-earnings-growth ratio of 1.81 and a beta of 1.33. The business's 50-day moving average price is $23.02 and its 200 day moving average price is $22.20.

Progyny (NASDAQ:PGNY - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.19 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.42 by ($0.23). The business had revenue of $332.87 million for the quarter, compared to analysts' expectations of $315.70 million. Progyny had a return on equity of 10.69% and a net margin of 4.28%.The firm's revenue was up 9.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.17 earnings per share. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. As a group, sell-side analysts expect that Progyny will post 0.6 earnings per share for the current fiscal year.

Insider Activity

In other Progyny news, Director Kevin K. Gordon sold 2,500 shares of the company's stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $22.04, for a total transaction of $55,100.00. Following the sale, the director owned 12,501 shares in the company, valued at $275,522.04. This represents a 16.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Allison Swartz sold 2,398 shares of Progyny stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $22.96, for a total value of $55,058.08. Following the completion of the transaction, the executive vice president owned 79,697 shares of the company's stock, valued at approximately $1,829,843.12. The trade was a 2.92% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 7,895 shares of company stock valued at $179,311. 9.40% of the stock is owned by corporate insiders.

Institutional Trading of Progyny

Institutional investors have recently added to or reduced their stakes in the business. Cetera Trust Company N.A boosted its holdings in shares of Progyny by 303.1% in the 2nd quarter. Cetera Trust Company N.A now owns 1,310 shares of the company's stock valued at $29,000 after buying an additional 985 shares during the period. BI Asset Management Fondsmaeglerselskab A S bought a new position in Progyny in the first quarter worth about $44,000. Militia Capital Partners LP boosted its stake in Progyny by 100.0% in the first quarter. Militia Capital Partners LP now owns 2,000 shares of the company's stock valued at $45,000 after acquiring an additional 1,000 shares during the period. Brooklyn Investment Group boosted its stake in Progyny by 5,216.4% in the first quarter. Brooklyn Investment Group now owns 3,243 shares of the company's stock valued at $72,000 after acquiring an additional 3,182 shares during the period. Finally, Canada Pension Plan Investment Board bought a new position in shares of Progyny during the second quarter valued at approximately $77,000. Institutional investors own 94.93% of the company's stock.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.